TrialEmerging infectious diseases2025

Efficacy and Safety of 4-Month Rifapentine-Based Tuberculosis Treatments in Persons with Diabetes.

Ekaterina V Kurbatova et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.